These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11551662)

  • 1. The cost of hepatitis C and the cost-effectiveness of its prevention.
    Shiell A; Law MG
    Health Policy; 2001 Nov; 58(2):121-31. PubMed ID: 11551662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating the cost-effectiveness of needle-syringe programs in Australia.
    Kwon JA; Anderson J; Kerr CC; Thein HH; Zhang L; Iversen J; Dore GJ; Kaldor JM; Law MG; Maher L; Wilson DP
    AIDS; 2012 Nov; 26(17):2201-10. PubMed ID: 22914579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model.
    Scott N; McBryde ES; Thompson A; Doyle JS; Hellard ME
    Gut; 2017 Aug; 66(8):1507-1515. PubMed ID: 27196586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of policies for the safe and appropriate use of injection in healthcare settings.
    Dziekan G; Chisholm D; Johns B; Rovira J; Hutin YJ
    Bull World Health Organ; 2003; 81(4):277-85. PubMed ID: 12764494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection.
    Sroczynski G; Esteban E; Conrads-Frank A; Schwarzer R; Mühlberger N; Wright D; Zeuzem S; Siebert U
    Eur J Public Health; 2009 Jun; 19(3):245-53. PubMed ID: 19196737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global epidemiology and burden of hepatitis C.
    Ray Kim W
    Microbes Infect; 2002 Oct; 4(12):1219-25. PubMed ID: 12467763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of hepatitis B vaccination of prison inmates.
    Pisu M; Meltzer MI; Lyerla R
    Vaccine; 2002 Dec; 21(3-4):312-21. PubMed ID: 12450707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort.
    Maier MM; Zhou XH; Chapko M; Leipertz SL; Wang X; Beste LA
    Dig Dis Sci; 2018 Jun; 63(6):1454-1462. PubMed ID: 29453610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling.
    Chhatwal J; Chen Q; Aggarwal R
    Infect Dis Clin North Am; 2018 Jun; 32(2):461-480. PubMed ID: 29778266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health and economic burden of diabetes in Bangladesh: Priorities for attention and control.
    Sarker AR; Sultana M
    J Diabetes; 2017 Dec; 9(12):1118-1119. PubMed ID: 28749030
    [No Abstract]   [Full Text] [Related]  

  • 12. Effectiveness and cost-effectiveness of nationwide campaigns for awareness and case finding of hepatitis C targeted at people who inject drugs and the general population in the Netherlands.
    Helsper CW; Janssen MP; van Essen GA; Croes EA; van der Veen C; de Wit AG; de Wit NJ
    Int J Drug Policy; 2017 Sep; 47():117-125. PubMed ID: 28826994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Making the economic case for prevention--a view from Wales.
    Hale J; Phillips CJ; Jewell T
    BMC Public Health; 2012 Jun; 12():460. PubMed ID: 22716189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of harm reduction in preventing hepatitis C among injection drug users.
    Pollack HA
    Med Decis Making; 2001; 21(5):357-67. PubMed ID: 11575485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
    Palmer AJ; Tucker DM
    Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of HIV counseling and testing in US prisons.
    Varghese B; Peterman TA
    J Urban Health; 2001 Jun; 78(2):304-12. PubMed ID: 11419583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
    Scott N; Doyle JS; Wilson DP; Wade A; Howell J; Pedrana A; Thompson A; Hellard ME
    Int J Drug Policy; 2017 Sep; 47():107-116. PubMed ID: 28797497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the effectiveness and efficiency of US HIV prevention efforts using scenario and cost-effectiveness analysis.
    Holtgrave DR
    AIDS; 2002 Nov; 16(17):2347-9. PubMed ID: 12441812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection.
    Deuffic-Burban S; Abiteboul D; Lot F; Branger M; Bouvet E; Yazdanpanah Y
    Gut; 2009 Jan; 58(1):105-10. PubMed ID: 18824553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic burden associated with patients diagnosed with hepatitis C.
    McCombs JS; Yuan Y; Shin J; Saab S
    Clin Ther; 2011 Sep; 33(9):1268-80. PubMed ID: 21840056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.